Investor Relations

Urigen is a privately held company.

If you are a current stock holder in Urigen Pharmaceuticals, please contact the company to obtain a password required to enter the financial information link. If you have your login information, please proceed to the Investor Secure Portal.

Press Releases

• Urigen Pharmaceuticals Initiates Multicenter Phase II Trial: “Evaluation of the Safety and Effectiveness of URG101 in Subjects with Interstitial Cystitis/Bladder Pain Syndrome”